Viewing Study NCT00191672



Ignite Creation Date: 2024-05-05 @ 11:57 AM
Last Modification Date: 2024-10-26 @ 9:17 AM
Study NCT ID: NCT00191672
Status: COMPLETED
Last Update Posted: 2007-01-26
First Post: 2005-09-12

Brief Title: A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer
Sponsor: Eli Lilly and Company
Organization: Eli Lilly and Company

Study Overview

Official Title: A Phase II Randomized Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Patients With Metastatic Breast Cancer
Status: COMPLETED
Status Verified Date: 2007-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The combination of docetaxel and gemcitabine has shown significant activity in patients with metastatic breast cancer Several studies have activity in patients of multiple lines of therapy including patients that have been treated with prior taxane therapy Overall responses have ranged from 30 to 79 The major side effects of the combination chemotherapy have been neutropenia anemia asthenia neuropathy nausea mucositis and neutropenic fever
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
B9E-US-S308 None None None